What this means
Researchers studied a protein called Cx43 that helps cells talk to each other. They found it may help a breast cancer drug slow tumor growth. This early work is not yet checked by other scientists, so it does not show this would help people.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- Human breast cancer cells in a lab
- Kind of research
- Early results, not yet checked by other scientists
The science
- Original title
- Dual Role of Cx43 in Enhancing CDK4/6 Inhibitor Response and Promoting the Elimination of Therapy-Induced Senescent Tumor Cells
- Authors
- Carpintero-Fernandez, P., Barturen-Gomez, M., Alvarez, V. et al.
- Journal
- bioRxiv (preprint, not yet peer reviewed)
- Published
- Oct 28, 2026
- Study type
- Preprint
Abstract
Breast cancer has become the most prevalent malignancy worldwide. A key clinical advance has been the introduction of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), that in combination with endocrine therapy has been a major advance for the treatment of luminal (ER/HER2-) breast cancer. CDK4/6i induce cell cycle arrest in G1 and cellular senescence improving clinical outputs. However, limited efficacy and therapeutic resistance remain major challenges due to incomplete effects or the failure to eliminate the accumulated tumor senescent cells. Here, we identify connexin 43 (Cx43), a membrane channel protein involved in cell-to-cell communication, identified as a novel target in luminal breast cancer that potentiates the effects of CDK4/6 inhibitors. We found that Cx43 not only reduces tumor cell proliferation by enhancing senescence but also reshapes the Senescence-Associated Secretory Phenotype (SASP) profile. We also demonstrate that, in combination with CDK4/6i, Cx43 reinforces G1 arrest via transcriptional downregulation of E2F targets including CDK4 and CDK6, and through interaction with p21/p27, deepens the senescent state. Importantly, the Cx43-associated senescent phenotype sensitizes tumor cells accumulated under CDK4/6i treatment to the senolytic agent Navitoclax. Our results demonstrate that upregulation of Cx43 in breast cancer reduces proliferation and enhances the clearance of therapy-induced senescent cells. The triple-drug strategy comprising CDK4/6i, Cx43 delivery, and a senolytic drug such as Navitoclax holds great promise for overcoming CDK4/6i resistance and improving clinical outcomes in ER/HER2- breast cancer and may also be applicable to other cancer types that respond to CDK4/6i or other pro-senescence antitumoral drugs.
Carpintero-Fernandez, P., Barturen-Gomez, M., Alvarez, V. et al. Dual Role of Cx43 in Enhancing CDK4/6 Inhibitor Response and Promoting the Elimination of Therapy-Induced Senescent Tumor Cells. bioRxiv. 2026. doi:10.64898/2026.10.26.761820. https://doi.org/10.64898/2026.10.26.761820
Related research
New fluorescent sensor detects cells aging from cancer and lung drugs
Researchers built a glowing probe that lights up only in certain aged cells. It may help scientists track these cells in living animals, but this is early lab work.
Mixing a senescence-clearing drug with trametinib slowed glioma regrowth in mice
Researchers found a drug combination that cleared aging-like tumour cells in mice and slowed regrowth. This does not show the combination would work the same way in children.
A vaccine-style treatment in mice eased diabetes signs and aged cell markers
Mice given a treatment aimed at a virus-like gene showed less weight gain and better blood sugar control. This study was in mice and cells, so it does not show the same would happen in people.
Aging cells that support stem cells may disrupt them through chemical signals
This is a review that pulls together older and newer studies. It proposes a model, but it does not show that the model is true.
A new vaccine clears aging cells in mice and may extend lifespan
Researchers made a vaccine aimed at old, worn-out cells called senescent cells. In mice, it cleared some of these cells and helped metabolism. This is early work, so it does not show the vaccine would help people.
Review of how the FOXO4 protein may guard cells against damage and aging
This review sorted past studies on FOXO4 by how directly they tested it. Some links are well supported, but many antioxidant effects are still based on related proteins.
See all research on Senolytics →